phase II clinical study
BerGenBio, Tempus Partner for Bemcentinib Trial in STK11-Mutant NSCLC
Tempus will provide clinical and molecular data to function as a synthetic control arm for an ongoing single-arm study of bemcentinib plus chemo and immunotherapy.
Reveal Genomics HER2DX Assay to Be Prospectively Evaluated in ECOG-ACRIN Trial
Researchers will analyze the ability of HER2DX scores to predict patient outcomes in the Phase II CompassHER2 pCR trial.
The organizers thought they would just build on the infrastructure of NCI-MATCH, but it has not been that easy.
Researchers hope their study will show that tests for gene variants and DNA methylation can predict which lower-risk patients may be cured without a stem cell transplant.
BostonGene, Prisma Health Partner to Study Molecular, Immune Profiles of Rare Tumors
BostonGene will analyze tissue and blood samples from patients with rare tumors enrolled in Prisma's Phase II immunotherapy study.